Cancer Leadership Council Urges Congress to Include Cancer Drug Parity in Year End Package
On November 22, 2022, the International Myeloma Foundation joined the Cancer Leadership Council in sending a letter to Congressional leaders surrounding public policy issues facing cancer patients. The letter touches on many issues including Medicare reimbursement policy, prior authorization reform, research funding, telehealth, diversity in clinical trials, and the Cancer Drug Parity Act.
As a reminder, the IMF leads coalition efforts surrounding the Cancer Drug Parity Act, a bill which ensures that patients are able to access their medications regardless if they are administered in a physician’s office or at home. We are thrilled that the Cancer Leadership Council included this important request and hopeful that Congress will consider the bill.